Risedronate

Drugs and Aging

Volumn 13, Issue 1, 1998, Pages 83-91

  Goa, Karen L ^a   Balfour, Julia A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ETIDRONIC ACID; GLUCOCORTICOID; RISEDRONIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE ATROPHY; BONE MASS; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ELIMINATION; GASTROINTESTINAL SYMPTOM; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PAIN; POSTMENOPAUSE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SUBCUTANEOUS DRUG ADMINISTRATION; TRABECULAR BONE;

EID: 0031855640     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199813010-00008     Document Type: Article

References (36)

1. Johansen A, Stone M, Rawlinson F. Bisphosphonates and the treatment of bone disease in the elderly. Drugs Aging 1996 Feb; 8: 113-26
2. Patel S. Drugs in development for the treatment of metabolic bone disease. Expert Opin Invest Drug 1996 Apr; 5: 429-45
3. Parker C, Hosking D. Treatment of osteoporosis: Bisphosphonates as an alternative to hormone replacement therapy. Curr Obstet Gynaccol 1996; 6 (4): 206-11
4. Licata AA. Bisphosphonate therapy. Am J Med Sci 1997 Jan; 313: 17-22
5. Richardson AC, Tinling SP, Chole RA. Risedronate activity in the fetal and neonatal mouse. Otolaryngol Head Neck Surg 1993 Oct; 109: 623-33
6. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995 Oct; 10: 1478-87
7. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including RAS. J Bone Miner Res 1998; 13 (4): 581-9
8. Boyce RW, Wronski TJ, Ebert DC, et al. Direct stereological estimation of three-dimensional connectivity in rat vertebrae: effect of estrogen, etidronate and risedronate following ovariectomy. Bone 1995 Feb; 16: 209-13
9. Lin BY, Jee WSS, Ma YF, et al. Effects of prostaglandin Ed2 and risedronate administration on cancellous bone in older female rats. Bone 1994 Sep-Oct; 15: 489-96
10. Ma Y, Chen YY, Jee WS, et al. Co-treatment of PGEd2 and risedronate is better than PGEd2 alone in the long-term treatment of ovariectomized-induced osteopenic rats. Bone 1995 Oct; 17 (4 Suppl.): 267S-72S
11. Liang HH, Ma YF, Jee WS, et al. Risedronate plus prostaglandin Ed2 is superior to prostaglandin Ed2 alone in maintaining the added hone after withdrawal in a non-growing bone site in ovariectomized rats. Bone 1995 Oct; 17 (4 Suppl.): 335S-9S
12. Ma YF, Lin BY, Jee WS, et al. Prostaglandin Ed2(PGEd2) and risedronate was superior to PGEd2 alone in maintaining newly added bone in the cortical bone site after withdrawal in older intact rats. J Bone Miner Res 1997 Feb; 12: 267-75
13. Jee WSS, Lin BY, Ma YF, et al. Extra cancellous bone induced by combined prostaglandin Ed2 and risedronate administration is maintained after their withdrawal in older female rats. J Bone Miner Res 1995 Jun; 10: 963-70
14. Boyce RW, Paddock CL, Gleason JR, et al. The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site. J Bone Miner Res 1995 Feb; 10: 211-21
15. Forwood MR, Burr DB, Takano Y, et al. Risedronate treatment does not increase microdamage in the canine femoral neck. Bone 1995 Jun; 16: 643-50
16. Sasaki A, Boyce BF, Story B, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995 Aug 15; 55: 3551-7
17. Hall DG, Stoica G. Effect of the hisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. J Bone Miner Res 1994 Feb; 9: 221-30
18. Blank MA, Ems BL, Gibson GW, et al. Nonclinical model for assessing gastric effects of bisphosphonates. Dig Dis Sci 1997 Feb; 42: 281-8
19. Mitchell DY, Barr WH, Eusebio RA, et al. Determination of intravenous pharmacokinetics, absolute and relative bioavailability, and intra- and intersubject variability of risedronate using a four period replicate study design [abstract no. 3444]. Pharm Res 1997; 14: S-610
20. Mitchell DY, Eusebio RA, Heise MA, et al. The effect of dosing regimen on the pharmacokinetics of risedronate administered to healthy subjects [abstract no. M661]. J Bone Miner Res 1996; 11: S347
21. Mitchell DY, Eusebio RA, Pallone KA, et al. Single dose linearity of risedronate following oral administration of 2.5, 5, or 30 mg to healthy volunteers [abstract no. 3443]. Pharm Res 1997; 14: S-609
22. Mitchell DY, Eusebio R, Axelrod DW, et al. Risedronate pharmacokinetics following single and multiple dose intravenous administration [abstract no. P321]. Bone 1997; 20: 100S
23. Mitchell DY, St Peter JV, Eusebio RA, et al. The effect of renal impairment on risedronate pharmacokinetics [abstract no. F472]. J Bone Miner Res 1997; 12: S344
24. Siris ES, Chines AA, Altman RD, et al. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Miner Res 1998: In press
25. Hosking DJ, Eusebio RA, Chines AA. Paget's disease of bone: reduction of disease activity with oral risedronate. Bone 1998; 22 (1): 51-5
26. Bekker PJ, Miller PD, Adachi JD, et al. Risedronate treatment improves pain status in patients with Paget's disease of hone (abstract no. T673). J Bone Miner Res 1997; 12 Suppl. 1
27. Brown JP, Kylstra JW, Bekker PJ, et al. Risedronate in Paget's disease: preliminary results of a multicenter study [abstract]. Semin Arthritis Rheum 1994 Feb; 23: 272
28. Mortensen L, Charles P, Bekker PJ, et al. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998; 83 (2): 396-402
29. Clemmesen B, Ravn P, Zegels B, et al. A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int 1997; 7: 488-95
30. McClung MR, Bensen W, Bolognese MA, et al. Risedronate increases BMD at the hip, spine and radius in postmenopausal women with low hone mass [abstract no. P269]. J Bone Miner Res 1997 Aug; 12 Suppl. 1: S169
31. Eastell R, Devogelaer JP, Pell NFA, et al. Risedronate therapy prevents bone loss in glucocorticoid-treated rheumatoid arthritis patients: a three-year study [abstract]. Inflammo-pharmacology 1997 Jun; 5: 186-8
32. Delmas PD, Balena R, Confravreux E, et al. Bisphosphonate risedronate prevents hone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997 Mar; 15: 955-62
33. Roux C, Ravaud P, Cohen-Solal M, et al. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 1994 Jan-Feb; 15: 41-9
34. Singer FR, Brown JP, Siris ES, et al. A safety review of risedronate in the treatment of Paget's disease of bone [abstract no. 1489]. Arthritis Rheum 1997; 40 Suppl.: S279
35. Ward C, Sacco-Gibson N, Mitchell DY, et al. Single dose risedronate (pyridinyl-bisphosphonate) does not induce acute phase reaction in healthy subjects [abstract no. M660]. J Bone Miner Res 1997; 11 Suppl. 1: S346
36. Sacco-Gibson N, Mitchell DY, Eusebio RA, et al. Risedronate (a pyridinyl bisphosphonate) does not induce acute phase reaction after single and multiple dose intravenous administration [abstract no. P329]. Bone 1997; 20: 102S